key: cord-0698801-nc43v9nf authors: Diallo, Alhassane; Pichelin, Matthieu; Wargny, Matthieu; Gourdy, Pierre; Bonnet, Jean‐Baptiste; Hadjadj, Samy; Cariou, Bertrand; Sultan, Ariane; Galtier, Florence title: Influenza vaccination and prognosis for COVID‐19 in hospitalized patients with diabetes: Results from the CORONADO study date: 2021-10-25 journal: Diabetes Obes Metab DOI: 10.1111/dom.14577 sha: 7eea7bfd63e0b870ca58c47a75af529057f38e34 doc_id: 698801 cord_uid: nc43v9nf nan Co-morbidities like diabetes confer higher susceptibility to several respiratory diseases such as influenza, invasive pneumococcal disease, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a greater risk of death in infected patients. 1, 2 For this reason, various organizations recommend routine vaccination against influenza and invasive pneumococcal disease to reduce the risk of hospitalization and death. 3 During the current coronavirus disease 2019 (COVID-19) pandemic, which has resulted in more than 205 million cases and more than 4.3 million deaths worldwide as of 12 August 2021, 4 it has been suggested that influenza vaccination might attenuate its severity. [5] [6] [7] Recent reports suggest that prior influenza vaccination is associated with decreased positive COVID-19 testing, is potentially protective from moderate and severe cases of COVID-19 with a lower incidence of clinical outcomes such as hospitalization or mortality regardless of co-morbidities, and reduces the burden of COVID-19. 6, 7 Conversely, an analysis of literature review found no evidence of a potentially protective role of the influenza vaccination in COVID-19 patients with influenza co-infection in terms of morbidity and mortality reduction. 8 Two theories have been provided to explain the association between lower odds of hospitalization or death in COVID-19-positive patients and prior administration of influenza vaccine. [9] [10] [11] The first one is related to the MF59 adjuvant within the flu vaccine, which may induce protective effects against COVID-19 by triggering a heightened immune response. 11 The second theory concerns the enhancing role of the flu vaccine in the activation of NK cells, which counterbalances the dramatically lower NK cell activity induced by SARS-CoV-2 infection. 9,10 Given the discrepant conclusions from the literature and the low prevalence of patients with diabetes (10%-13%) in these studies, 6 hospitals during the first wave of the pandemic, provided an opportunity to address this matter. 12 In the current analysis, we therefore report data on an association between influenza vaccination during the year before hospitalization and COVID-19-related severe outcomes in patients with diabetes. Data used for the current analysis were obtained from the nationwide multicentre observational CORONADO study (ClinicalTrial.gov NCT04324736). The protocol and study design have been previously reported elsewhere. 12 The influenza vaccination status was obtained from each patient/family by asking if they had been vaccinated against influenza in the current season. Only patients with available information on vaccination status were considered in the analysis. The composite primary outcome (CPO) combined invasive mechanical ventilation and/or death within 7 days. 12 Secondary outcomes were invasive mechanical ventilation, death, and admission to an intensive care unit (ICU) within 7 days and similar outcomes (including CPO) 28 days after hospitalization. Descriptive statistics (frequencies and percentages, mean and standard deviations [SD], or median and interquartile ranges) were used to present the demographic and clinical characteristics of participants at baseline. For comparisons between vaccinated and unvaccinated patients, appropriate tests were used (t test or Wilcoxon for quantitative variables and Fisherʼs exact test for categorical variables). Cox and logistic (for ICU admission) regression models were used to compare the difference in COVID-19-related severity between vaccinated and unvaccinated patients. To account for missing data, we performed multiple imputation by chained equations with five replications. Then we computed a propensity score (PS) to control for confounding factors that might influence vaccination uptake. Thus, the analyses with and without adjustment were performed on the same number of patients. Adjusted Cox and logistic regressions were applied to estimate the average effect on influenza vaccine as inverse probability of treatment weighting (IPTW). 13 The standardized mean difference method was used to assess the balance of covariates between the vaccination groups before and after weighting. Assumption of hazard proportionality and log-linearity were verified. All data analyses were conducted with R software (4.0.3). Note: Bolded p values were < 0.05, which means the influenza vaccine was significantly associated with outcomes (combined primary outcome, invasive mechanical ventilation, and death). a The propensity score was constructed for age, sex, body mass index, tobacco use, alcohol use, history of hypertension, ischaemic heart disease, heart failure, stroke, peripheral artery disease, diabetic kidney disease, retinopathy, dyslipidaemia, HbA1c, respiratory failure and/or chronic obstructive pulmonary disease, treatment for obstructive sleep apnoea, active cancer, and the use of metformin, insulin, dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1, statin, thiazide diuretic, potassium-sparing diuretic, acarbose, sulphonylurea/glinide, angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker, beta blocker, antiplatelet agent, and anticoagulant. b For ICU admission, the vaccine effects size was expressed using odds ratio. Figure S1 ), no significant association was found between influenza vaccination and the primary outcome (1.04, 0.68-1.57) or its individual component at day 7 or day 28 (Table 1) . To the best of our knowledge, this is the first study to address the impact of seasonal influenza vaccination on COVID-19 severity in patients with diabetes. While we did not find an association between influenza vaccination and the severity of COVID-19, two recent US studies have shown a beneficial effect of influenza vaccination. 6 One possible explanation for this observed discrepancy compared with our report is that CORONADO patients were older and more frequently affected by co-morbidities, and therefore were associated with a more severe clinical and biological presentation upon admission. Indeed, in the two US studies, the mean age of patients ranged from 40.7 to 48.4 years with a prevalence of diabetes of 9%-11%, 6, 7 whereas all our patients had diabetes. Another possible explanation for this discrepancy is the difference in statistical method used to estimate the influenza vaccine effect, especially in the Florida report, with an absence of the inverse probability of treatment weighting by covariates to control for confounders. 7 In the current study, information on influenza vaccination was available for 29.3% of the whole sample, of whom 46% received the vaccine, while 28% were followed by a diabetologist. MW reports personal fees from Novo Nordisk. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021 Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations Impact of the influenza vaccine on COVID-19 infection rates and severity Influenza vaccination and hospitalizations among COVID-19 infected adults Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality The potential effect of novel coronavirus SARS-CoV-2 on NK cells; a perspective on potential therapeutic interventions Control of human viral infections by natural killer cells Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORO-NADO study The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies Trends in seasonal influenza vaccine coverage of target groups in France, 2006/07 to 2015/16: impact of recommendations and 2009 influenza A(H1N1) pandemic Seasonal influenza vaccination among people with diabetes: influence of patientsʼ characteristics and healthcare use on behavioral changes We thank the sponsor (DRCI CHU Nantes), Clinical Project Manager (Maëva Saignes) and assistant (Jeanne Saunier), Clinical Research Associates (Selma El Andaloussi, Joëlle Martin-Gauthier, Emily Rebouilleau), and data manager (Tanguy Roman). We thank the Com- AD analysed data and wrote the first draft. FG and AS initiated the study, interpreted the data, and reviewed the manuscript. MW and J-BB realized data preparation and reviewed the manuscript. BC, PG, MP, and SH designed the CORONADO study and reviewed the manuscript. The peer review history for this article is available at https://publons. com/publon/10.1111/dom.14577. Data available on request from the authors The data that support the findings of this study are available from the corresponding author upon reasonable request.